Literature DB >> 21983008

Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative.

Margery L S Gass1, Barbara B Cochrane, Joseph C Larson, Joann E Manson, Vanessa M Barnabei, Robert G Brzyski, Dorothy S Lane, June LaValleur, Judith K Ockene, Charles P Mouton, David H Barad.   

Abstract

OBJECTIVE: The aim of this study was to determine the patterns and predictors of sexual activity in the Hormone Therapy (HT) Trials of the Women's Health Initiative (WHI).
METHODS: Sexual activity questions were administered to 27,347 women ages 50 to 79 years at baseline and at year 1 and to a random 8.6% subsample at years 3 and 6. The associations with demographic and health characteristics were determined.
RESULTS: Sexual activity at baseline was 60.7%, 44.9%, and 28.2% in the 50- to 59-, 60- to 69-, and 70- to 79-year-old age groups, respectively. Most of the participants were satisfied with their current sexual activity (63.2%). Of those dissatisfied, 57% preferred more sexual activity. Vaginal atrophy correlated with sexual inactivity at baseline (P < 0.001). The correlates associated with stopping sexual activity at year 1 included poor/fair self-rated health, lack of satisfaction with quality of life, depression, and loss of partner (P < 0.001). The strongest predictor of sexual activity at year 1 was sexual activity at baseline (odds ratio, 96.71; 95% CI, 81.90-114.20). A subset analysis of women adherent with HT or placebo at years 3 and 6 suggested that HT was associated with a higher percentage of participants reporting sexual activity (P = 0.01).
CONCLUSIONS: Most women in the WHI HT Trials were satisfied with their sexual activity. Of those who were dissatisfied, the majority preferred more, rather than less, sexual activity. Vaginal atrophy at baseline correlated with sexual inactivity, and sexual activity at baseline was the strongest identified predictor of sexual activity at year 1. HT use was not predictive of ongoing sexual activity in the intent-to-treat analysis. This report further characterizes the participants in the WHI HT trials and reveals the complexity of factors related to the prevalence of sexual activity and satisfaction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983008     DOI: 10.1097/gme.0b013e3182227ebd

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  18 in total

Review 1.  Menopause and Sexuality.

Authors:  Kimberley Thornton; Judi Chervenak; Genevieve Neal-Perry
Journal:  Endocrinol Metab Clin North Am       Date:  2015-09       Impact factor: 4.741

2.  Association of sleep disturbance and sexual function in postmenopausal women.

Authors:  Juliana M Kling; JoAnn E Manson; Michelle J Naughton; M'hamed Temkit; Shannon D Sullivan; Emily W Gower; Lauren Hale; Julie C Weitlauf; Sara Nowakowski; Carolyn J Crandall
Journal:  Menopause       Date:  2017-06       Impact factor: 2.953

3.  The 2012 hormone therapy position statement of: The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2012-03       Impact factor: 2.953

4.  Blood Pressure, Sexual Activity, and Dysfunction in Women With Hypertension: Baseline Findings From the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Capri G Foy; Jill C Newman; Dan R Berlowitz; Laurie P Russell; Paul L Kimmel; Virginia G Wadley; Holly N Thomas; Alan J Lerner; William T Riley
Journal:  J Sex Med       Date:  2016-09       Impact factor: 3.802

5.  Using Wood's Light as a Diagnostic Tool for Vaginal Atrophy.

Authors:  Mustafa Ulubay; Mustafa Ozturk; Ulas Fidan; Ugur Keskin; Ibrahim Alanbay; Riza Karaca
Journal:  J Clin Diagn Res       Date:  2015-01-01

6.  Is Interpersonal Abuse Associated with Sexual (Dis)satisfaction among Postmenopausal Women?

Authors:  Erika L Kelley; M Brad Cannell; Margery Gass; Shawnita Sealy-Jefferson; Nancy F Woods; Chloe E Bird; Marcia L Stefanick; Julie C Weitlauf
Journal:  Womens Health Issues       Date:  2019-07-02

7.  Change in sexual functioning over the menopausal transition: results from the Study of Women's Health Across the Nation.

Authors:  Nancy E Avis; Alicia Colvin; Arun S Karlamangla; Sybil Crawford; Rachel Hess; L Elaine Waetjen; Maria Brooks; Ping G Tepper; Gail A Greendale
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

8.  Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.

Authors:  Margery Gass; Joseph Larson; Barbara Cochrane; JoAnn E Manson; Dorothy Lane; Vanessa Barnabei; Judith Ockene; Marcia L Stefanick; Charles Mouton
Journal:  Menopause       Date:  2018-03       Impact factor: 2.953

9.  Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT).

Authors:  Holly N Thomas; Gregory W Evans; Dan R Berlowitz; Glenn M Chertow; Molly B Conroy; Capri G Foy; Stephen P Glasser; Cora E Lewis; William T Riley; Laurie Russell; Olubunmi Williams; Rachel Hess
Journal:  J Hypertens       Date:  2016-06       Impact factor: 4.844

10.  Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy.

Authors:  Sharon J Parish; Rossella E Nappi; Michael L Krychman; Susan Kellogg-Spadt; James A Simon; Jeffrey A Goldstein; Sheryl A Kingsberg
Journal:  Int J Womens Health       Date:  2013-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.